| ALT | Alanine Aminotransferase |
| ASCO | American Society of Clinical Oncology |
| AST | Aspartate Aminotransferase |
| BSA | Body Surface Area |
| CCR | Complete Control Rate |
| CI | Confidence Interval |
| CINV | Chemotherapy-induced Nausea and Vomiting |
| CRR | the complete response rate |
| CTCAE | the Common Terminology Criteria for Adverse Events |
| DEX | Dexamethasone |
| ECG | Electrocardiogram |
| ECOG | Eastern Cooperative Oncology Group |
| ESMO | European Society for Medical Oncology |
| HEC | Highly Emetogenic Chemotherapy |
| MASCC | Multinational Association of Supportive Care in Cancer |
| MEC | Moderately Emetogenic Chemotherapy |
| mITT | the modified intention-to-treat population |
| NCCN | National Comprehensive Cancer Network |
| NEPA | Netupitant-Palonoseton |
| NK-1 RA | NK-1 receptor antagonist |
| PPS | Per-protocol Set |
| QTcB | QT interval corrected by Bazett’s formula |
| RCT | Randomized Controlled Trial |
| SAE | Serious Adverse Event |
| TCR | Total Control Rate |
| TRAE | Treatment-Related Adverse Event |
| 5-HT3 | 5-hydroxytryptamine-3 |